Cork Breast Cancer Trial to Pioneer Personalized Treatment Using Blood Tests
A new clinical trial opening in October at Cork University Hospital will investigate whether routine blood tests can map the genetic makeup of advanced breast cancers, offering patients a less invasive alternative to traditional tissue biopsies and aiming to deliver more targeted treatment plans.
- The MELODY trial opens for patient recruitment in October, running for an initial two-year period at Cork University Hospital and the CUH/UCC Cancer Centre for 50 women across the Cork and Kerry region.
- Developed by Dr. Emer Lynch via a Breakthrough Clinical Cancer Research Fellowship, the study investigates liquid biopsies to detect genetic alterations in cancer cells without requiring invasive tumour tissue biopsies.
- The initiative receives funding from Breakthrough Cancer Research, the Breast Cancer Research Foundation, the Health Research Board, and industry partners, addressing a significant diagnostic gap in Irish public healthcare where liquid testing is not currently routine.
The Clinical Problem in Advanced Breast Cancer Care
Breast cancer remains the most common cancer among women in Ireland, affecting approximately one in seven individuals. For patients diagnosed with advanced or metastatic stages, treatment decisions traditionally rely heavily on tissue biopsies. These procedures are frequently time-consuming, costly, and physically invasive for patients dealing with progressive disease. According to findings reported by the Irish Times and Irish Examiner, the current standard of care leaves significant clinical blind spots regarding how tumors mutate and adapt over time.
When tumors metastasize, capturing their evolving genetic characteristics requires frequent monitoring. Tissue biopsies cannot always be repeated safely or easily, leaving clinicians with limited options to track treatment resistance dynamically. To bridge this diagnostic gap, healthcare providers must evaluate emerging protocols. For individuals seeking specialized diagnostic evaluations or personalized management strategies, connecting with vetted [Relevant Oncology Specialist / Diagnostic Center] provides essential access to advanced clinical guidance.
How the MELODY Trial Uses Liquid Biopsies
Set to launch in October, the MELODY trial will enroll 50 patients over a two-year period across Cork and Kerry. Developed through a Breakthrough Clinical Cancer Research Fellowship awarded to Dr. Emer Lynch, the research program aims to determine whether a simple blood draw can capture the actionable genetic mutations driving tumor growth.
Dr. Emer Lynch stated that the trial will “investigate the use of a simple blood test, known as a liquid biopsy, to identify genetic changes in cancer cells.” The objective is to give clinicians additional data regarding an individual’s specific tumor architecture, helping inform personalized treatment decisions without subjecting patients to repeated surgical tissue extractions.
Patients such as Aislinn Higgins, a 48-year-old participant who was diagnosed with breast cancer in 2021 and subsequently underwent brain surgery in 2023 after the disease spread, served on the patient advisory group for the trial design. Describing the initiative as a positive step, Ms. Higgins noted in reports by the Irish Examiner that liquid testing could reduce procedural uncertainty for patients facing metastatic diagnoses. “This trial will hopefully, in the future, lead to more treatment options and more individualised treatment plans for patients with advanced/metastatic breast cancers,” Ms. Higgins said.
Funding, Collaboration, and Regulatory Landscape
Translating novel biomarkers into public healthcare pathways requires robust financial backing and cross-sector collaboration.
Liquid biopsy testing of this nature is not currently standard within routine public care in Ireland. Clinical researchers intend for this two-year window to generate the robust evidence required to demonstrate clinical utility and cost-effectiveness. For healthcare facilities and clinics seeking to align their diagnostic frameworks with evolving translational oncology standards, consulting with [Relevant Healthcare Compliance / Clinical Operations Service] ensures regulatory adherence and seamless integration of new laboratory assays.
Future Trajectory of Personalised Oncology
As clinical research shifts toward non-invasive monitoring, the integration of liquid biopsies into mainstream oncology protocols represents a fundamental change in disease management. By identifying actionable mutations early and tracking therapeutic efficacy in real-time, oncologists can pivot treatment regimens before clinical progression occurs. Interested patients and medical professionals can reach out directly via email at uccctg@ucc.ie to inquire about trial eligibility criteria and recruitment updates.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*